Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Can Fite BioPharma Ltd CANF

Healthcare Biotechnology
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NYSEAM:CANF)

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

GlobeNewswire 3 days ago

Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

GlobeNewswire 3 days ago

Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson

GlobeNewswire February 17, 2026

Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy

GlobeNewswire February 9, 2026

Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson

GlobeNewswire February 5, 2026

Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson

GlobeNewswire January 20, 2026

Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction

GlobeNewswire December 26, 2025

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

GlobeNewswire December 23, 2025

Can-Fite Provides Update on Clinical and Financial Status

GlobeNewswire December 16, 2025
View More News ››

Opinion & Analysis (NYSEAM:CANF)

Biopharma Reports Consistent 'Phase 2 Liver Fat (NASH and NAFLD) Results'

Streetwise Reports April 23, 2020

Biopharma Signs Multimillion-Dollar Deal for Key Products in China

Streetwise Reports August 8, 2018
View More Opinion ››

Bullboard Posts (NYSEAM:CANF)

CANF - Isn't Done Yet

<< View Post To Watch Video >>
HDavis - December 20, 2021

CANF - Huge News

<< View Post To Watch Video >>
HDavis - December 20, 2021

RE:CANF

Hahahahaha..... how did that work out for you?   Averaged down yet?
RandomGuy1 - November 19, 2021

CANF

Might be about time to re-enter.
fnapts - February 25, 2021
View more Bullboard ››

Avrupa Minerals Ltd.

Avrupa Minerals Ltd.

Avrupa Minerals Ltd., a junior exploration and development company, engages in the acquisition and exploration of mineral ...
View More »

Podcasts